Pathogen List Development Guided By Limited Therapy Availability – Cmte.
Executive Summary
Limited treatment availability due to multi-drug resistance should be the most important factor in determining whether a pathogen is "of public health importance" for drug development, members of FDA's Anti-Infective Drugs Advisory Committee said
You may also be interested in...
Antibiotic Research Stalling In Conversion Of Target Into New Drug
Translating validated targets into clinical candidates is the major hurdle in discovering new antibiotics to combat resistance, Lilly VP-Scientific Affairs Gail Cassell, PhD, suggested in a presentation to FDA's Center for Drug Evaluation & Research Jan. 7
Antibiotic Research Stalling In Conversion Of Target Into New Drug
Translating validated targets into clinical candidates is the major hurdle in discovering new antibiotics to combat resistance, Lilly VP-Scientific Affairs Gail Cassell, PhD, suggested in a presentation to FDA's Center for Drug Evaluation & Research Jan. 7
Antibiotic Trial Without Comparator Would Lower R&D Cost, Wyeth Exec Says
Antibiotic trials without comparator drug arms would lower development costs, Wyeth Antibacterial Research Director Steven Projan, PhD, suggested